SCHEMBL4248924

SCHEMBL4248924

O=C(O)c1cccc(-c2ccc(C(=O)N3CCOCC3)cc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.73
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
RAB9A P51151 1/20 0.67
ERN1 O75460 2/20 0.60
TSHR P16473 1/20 0.58
ALDH1A1 P00352 1/20 0.58
AOC3 Q16853 1/20 0.56
MAPK1 P28482 1/20 0.55
PHGDH O43175 1/20 0.54
KMO O15229 2/20 0.54
POLB P06746 1/20 0.54
SLC6A7 Q99884 1/20 0.54
JAK2 O60674 2/20 0.53
PLK4 O00444 1/20 0.53
MAP4K4 O95819 1/20 0.53
ROS1 P08922 1/20 0.53
FGFR1 P11362 1/20 0.53
FLT1 P17948 1/20 0.53
MARK3 P27448 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7222464 0.94 HPGD (0.78) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL4245858 0.93 HPGD (0.74) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL14508043 0.88 HPGD (0.71) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL4249493 0.87 HPGD (0.73) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL8150805 0.87 HPGD (0.76) HPGDMEN1KMT2ARAB9ATSHR
SCHEMBL30577960 0.85 L3MBTL1 (0.64) HPGDMEN1KMT2ARAB9ATSHR
SCHEMBL1199986 0.85 L3MBTL1 (0.64) HPGDMEN1KMT2ARAB9ATSHR
SCHEMBL28860346 0.84 HPGD (1.00) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL13952065 0.83 HPGD (0.65) HPGDMEN1KMT2ARAB9AERN1
SCHEMBL17024130 0.83 KMO (0.73) HPGDMEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025093558-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2025-05-08 WO disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
EP-1960367-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2008-08-27 EP disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX HPGD 13/4885MEN1 4409/4885KMT2A 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.